# HDCRT Plus Pembrolizumab in Advanced Malignancies

> **NCT02987166** · PHASE1 · COMPLETED · sponsor: **James Larner, MD** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **RADIATION:** High-Dose Conformal Radiation Therapy
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02987166
- **Lead sponsor:** James Larner, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-21
- **Primary completion:** 2020-01-13
- **Final completion:** 2020-02-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02987166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02987166, "HDCRT Plus Pembrolizumab in Advanced Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02987166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*